View ValuationProQR Therapeutics 将来の成長Future 基準チェック /26ProQR Therapeuticsは、15.3%と49%でそれぞれ年率15.3%で利益と収益が成長すると予測される一方、EPSはgrowで24.1%年率。主要情報15.3%収益成長率24.12%EPS成長率Biotechs 収益成長25.3%収益成長率49.0%将来の株主資本利益率n/aアナリストカバレッジGood最終更新日17 May 2026今後の成長に関する最新情報Major Estimate Revision • May 13Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €19.4m to €15.2m. Forecast losses increased from -€0.505 to -€0.525 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$8.88 unchanged from last update. Share price was steady at US$1.70 over the past week.Major Estimate Revision • Mar 19Consensus revenue estimates increase by 11%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from €17.7m to €19.5m. Forecast losses expected to reduce from -€0.539 to -€0.487 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$8.88 unchanged from last update. Share price fell 7.6% to US$1.59 over the past week.Major Estimate Revision • Nov 13Consensus revenue estimates decrease by 19%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €20.1m to €16.3m. EPS estimate unchanged from -€0.42 per share at last update. Biotechs industry in the US expected to see average net income decline 9.7% next year. Consensus price target of US$8.88 unchanged from last update. Share price fell 9.2% to US$2.16 over the past week.Price Target Changed • May 14Price target decreased by 7.8% to US$8.88Down from US$9.63, the current price target is an average from 8 analysts. New target price is 473% above last closing price of US$1.55. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.32 last year.Price Target Changed • Mar 30Price target increased by 13% to US$10.67Up from US$9.43, the current price target is an average from 6 analysts. New target price is 662% above last closing price of US$1.40. Stock is down 39% over the past year. The company is forecast to post a net loss per share of €0.39 next year compared to a net loss per share of €0.32 last year.Major Estimate Revision • Mar 20Consensus revenue estimates increase by 12%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €13.7m to €15.3m. EPS estimate fell from -€0.369 to -€0.394 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$9.43 to US$9.71. Share price fell 12% to US$1.63 over the past week.すべての更新を表示Recent updatesReported Earnings • May 14First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: €0.13 loss per share (further deteriorated from €0.096 loss in 1Q 2025). Revenue: €2.03m (down 57% from 1Q 2025). Net loss: €13.4m (loss widened 33% from 1Q 2025). Revenue missed analyst estimates by 61%. Earnings per share (EPS) also missed analyst estimates by 9.2%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 13Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €19.4m to €15.2m. Forecast losses increased from -€0.505 to -€0.525 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$8.88 unchanged from last update. Share price was steady at US$1.70 over the past week.お知らせ • May 06ProQR Therapeutics N.V., Annual General Meeting, Jun 02, 2026ProQR Therapeutics N.V., Annual General Meeting, Jun 02, 2026. Location: allen overy shearman sterling llp, apollolaan 15, 1077, ab in amsterdam, netherlands, amsterdam NetherlandsNew Risk • Apr 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€43m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).お知らせ • Apr 08ProQR Therapeutics N.V. Establishes AI Advisory BoardProQR Therapeutics N.V. has established an AI Advisory Board comprising leaders from the AI and techbio fields to support the development of the Company’s AI strategy for Axiomer. Members of the ProQR AI Advisory Board include: Eric Durand, PhD, Chief Data Science Officer, Owkin; David Ruau, PhD, Head of BD EMEA, Healthcare & Life Sciences, NVIDIA; Thomas Wolf, Co-Founder and Chief Science Officer of Hugging Face; Gerard van Westen, Full Professor AI and Medicinal Chemistry at Leiden University; Romain Lacombe, Venture Partner, HCVC; Imran Haque, PhD, Chief Technology Officer, Kimia Therapeutics.Major Estimate Revision • Mar 19Consensus revenue estimates increase by 11%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from €17.7m to €19.5m. Forecast losses expected to reduce from -€0.539 to -€0.487 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$8.88 unchanged from last update. Share price fell 7.6% to US$1.59 over the past week.Board Change • Mar 17High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 3 experienced directors. 1 highly experienced director. Member of Scientific Advisory Board Phil Zamore is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Mar 13Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: €0.40 loss per share (further deteriorated from €0.32 loss in FY 2024). Revenue: €16.3m (down 16% from FY 2024). Net loss: €42.2m (loss widened 52% from FY 2024). Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) exceeded analyst estimates by 5.0%. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.お知らせ • Feb 10ProQR Therapeutics N.V. Announces Planned Changes to Board CompositionProQR Therapeutics N.V. announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting (AGM) as their terms conclude. The planned changes to ProQR’s Board composition at its 2026 AGM reflect the Company’s development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planning. An executive search firm has been engaged to assist ProQR in identifying candidates to be nominated to the Board to support long-term value creation for all its stakeholders. As part of its ongoing governance practices, the Board regularly reviews its composition to ensure it maintains an appropriate balance of skills, experience, and perspectives to support ProQR’s long-term strategic objectives. This process has resulted in the appointment of two new Board members in the last three years.分析記事 • Jan 13Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price PlungeTo the annoyance of some shareholders, ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shares are down a considerable 28% in...お知らせ • Jan 08Proqr Therapeutics N.V. Announces Encouraging Ax-0810 Phase 1 Safety and Pk Data, Development Candidate SelectionsProQR Therapeutics N.V. announced encouraging initial safety and PK data from the first cohort of healthy volunteers in its ongoing Phase 1 trial of AX-0810 and provided an update on broader pipeline progress and anticipated 2026 milestones. The ongoing Phase 1 study of AX-0810 is a single-center, randomized, double-blind, placebo-controlled, multiple dose escalation study being conducted in healthy volunteers in the Netherlands. Up to 33 participants will be enrolled, including 24 receiving AX-0810 and 9 receiving placebo, across 3 dose cohorts. Participants receive 4 subcutaneous injections over 4 weeks followed by a 12-week safety follow-up period. A Data Monitoring Committee reviews safety data prior to each dose escalation. The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics (PK) of AX-0810 and to confirm target engagement as measured by biomarkers (EUCT number: 2025-521876-77-00).: Based on initial 4-week safety and PK data from participants dosed in Cohort 1 (3mg/kg), AX-0810 demonstrated a safety profile with no serious adverse events or clinically meaningful laboratory abnormalities observed to date. Preliminary pharmacokinetic observations are in line with non-clinical data, supporting continued dosing per the study design. ProQR remains on track to report target engagement data for healthy volunteer cohorts in the first half of 2026. In parallel, activities are underway to include a patient cohort in this Phase 1 first-in-human trial following the healthy volunteer cohorts. In addition to AX-0810, ProQR continues to advance earlier-stage pipeline programs from its Axiomer RNA editing platform, with Development Candidates selected for pipeline programs AX-2402 and AX-2911. AX-2402 is the Company’s development program targeting MECP2 for Rett syndrome (R270X). ProQR selected a Development Candidate for AX-2402 based on a robust preclinical profile supporting advancement to development activities, with the objective of initiating a first-in-human clinical trial in the first half of 2027. ProQR also announced non-clinical proof-of-concept data generated in a mouse model of Rett syndrome with the MECP2 R270X mutation. Treatment with AX-2402 resulted in statistically significant and clinically relevant functional improvements. These effects included improvement in cumulative Bird score, driven in part by robust improvements in hindlimb clasping score. Further details and analyses will be presented at a later date. AX-2402 is supported by funding of up to $9.2M from the Rett Syndrome Research Trust (RSRT).New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€51m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).分析記事 • Nov 24ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 29% Share Price Plunge Could Signal Some RiskProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders won't be pleased to see that the share price has had a very rough...Major Estimate Revision • Nov 13Consensus revenue estimates decrease by 19%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €20.1m to €16.3m. EPS estimate unchanged from -€0.42 per share at last update. Biotechs industry in the US expected to see average net income decline 9.7% next year. Consensus price target of US$8.88 unchanged from last update. Share price fell 9.2% to US$2.16 over the past week.Reported Earnings • Nov 07Third quarter 2025 earnings released: €0.10 loss per share (vs €0.099 loss in 3Q 2024)Third quarter 2025 results: €0.10 loss per share (further deteriorated from €0.099 loss in 3Q 2024). Revenue: €2.92m (down 27% from 3Q 2024). Net loss: €11.0m (loss widened 36% from 3Q 2024). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.分析記事 • Nov 05Is ProQR Therapeutics (NASDAQ:PRQR) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Oct 21ProQR Therapeutics N.V. Receives CTA Authorization for AX-0810ProQR Therapeutics N.V. announced that following review under the new European Medicines Agency (EMA) centralized review process, the Central Committee on Research Involving Human Subjects (CCMO) has authorized ProQR’s Clinical Trial Application (CTA) for a Phase 1 study of AX-0810 in healthy volunteers. AX-0810 is the Company’s lead investigational editing oligonucleotide (EON) targeting NTCP, which is being developed for the treatment of cholestatic diseases like primary sclerosing cholangitis and biliary atresia. With this CTA approval, ProQR is authorized to begin dosing in its Phase 1 study, which is being conducted in the Netherlands. The Phase 1 study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) via biomarkers to establish proof of target engagement. AX-0810 is a first-in-class investigational RNA editing oligonucleotide (EON) that harnesses the body’s endogenous ADAR enzymes to selectively modulate NTCP function. Through this novel mechanism, AX-0810 aims to reduce toxic bile acid accumulation in the liver and improve outcomes in cholestatic diseases, which are characterized by inflammation, fibrosis, and progressive liver failure. By targeting a key pathogenic process that drives disease progression, AX-0810 has the potential to be disease-modifying. AX-0810 is the first program from ProQR’s Axiomer™ RNA editing pipeline to enter clinical development and is being evaluated in a Phase 1 trial in healthy volunteers focused on safety, pharmacokinetics, and biomarkers of target engagement to inform future studies in patients.分析記事 • Oct 10ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Price Is Out Of Tune With RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 13.3x ProQR Therapeutics N.V. ( NASDAQ:PRQR ) is a stock...Reported Earnings • Aug 08Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: €0.12 loss per share (further deteriorated from €0.033 loss in 2Q 2024). Revenue: €3.98m (down 39% from 2Q 2024). Net loss: €12.2m (loss widened 352% from 2Q 2024). Revenue missed analyst estimates by 7.7%. Earnings per share (EPS) also missed analyst estimates by 50%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.お知らせ • Jun 27Proqr Announces Cta Submission for Phase 1 Study of Ax-0810 Targeting NtcpProQR Therapeutics NV announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases. Axiomer "Editing Oligonucleotides", or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA - an Inosine is translated as a Guanosine (G) - correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.分析記事 • Jun 13ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than ExpectedProQR Therapeutics N.V. ( NASDAQ:PRQR ) shares have had a really impressive month, gaining 27% after a shaky period...分析記事 • May 27Here's Why ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO May Deserve A RaiseKey Insights ProQR Therapeutics' Annual General Meeting to take place on 3rd of June CEO Daniel de Boer's total...Price Target Changed • May 14Price target decreased by 7.8% to US$8.88Down from US$9.63, the current price target is an average from 8 analysts. New target price is 473% above last closing price of US$1.55. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.32 last year.分析記事 • May 09New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)Celebrations may be in order for ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders, with the analysts delivering a...Reported Earnings • May 09First quarter 2025 earnings released: €0.096 loss per share (vs €0.094 loss in 1Q 2024)First quarter 2025 results: €0.096 loss per share (further deteriorated from €0.094 loss in 1Q 2024). Revenue: €4.74m (up 1.7% from 1Q 2024). Net loss: €10.1m (loss widened 32% from 1Q 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.New Risk • May 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€63m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding).お知らせ • May 02ProQR Therapeutics N.V., Annual General Meeting, Jun 03, 2025ProQR Therapeutics N.V., Annual General Meeting, Jun 03, 2025. Location: 1530 cest at the offices, allen overy shearman sterling llp, amsterdam Netherlands分析記事 • Apr 14ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34%To the annoyance of some shareholders, ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shares are down a considerable 34% in...お知らせ • Apr 14+ 1 more updateProQR Therapeutics N.V. Announces Chief Financial Officer ChangesProQR Therapeutics NV. announced the appointment of Dennis Hom as Chief Financial Officer (CFO). The key leadership appointment support the advancement of the Company’s Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage. Dennis Hom, most recently CFO and Head of Corporate Development at Sagimet Biosciences, brings over 25 years of financial leadership across public and private biotech companies. He has raised more than $4.5 billion in capital and executed transactions totaling over $57 billion in disclosed value. At Sagimet, he led multiple financings, including its IPO, and executed a transformational licensing transaction. Earlier in his career, Mr. Hom held roles in business development and M&A at Amgen and Novartis, following investment banking experience at Hambrecht & Quist and its mergers with Chase and JP Morgan, where he advised biotech companies on capital strategy and M&A. He holds a bachelor's degree in biology from the Massachusetts Institute of Technology, where he conducted research in the lab of Nobel Laureate H. Robert Horvitz. At ProQR, Mr. Hom will oversee all corporate development functions, including corporate finance, investor relations, and business development. Chief Financial Officer Jurriaan Dekkers will be stepping down from their roles, having played key roles in supporting the Company’s strategic transition to a focused RNA editing platform. The executive will remain with the Company during a transitional period to ensure continuity.Price Target Changed • Mar 30Price target increased by 13% to US$10.67Up from US$9.43, the current price target is an average from 6 analysts. New target price is 662% above last closing price of US$1.40. Stock is down 39% over the past year. The company is forecast to post a net loss per share of €0.39 next year compared to a net loss per share of €0.32 last year.Major Estimate Revision • Mar 20Consensus revenue estimates increase by 12%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €13.7m to €15.3m. EPS estimate fell from -€0.369 to -€0.394 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$9.43 to US$9.71. Share price fell 12% to US$1.63 over the past week.Reported Earnings • Mar 13Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: €0.32 loss per share (improved from €0.35 loss in FY 2023). Revenue: €19.5m (up 196% from FY 2023). Net loss: €27.8m (loss narrowed 1.3% from FY 2023). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 7.3%. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.分析記事 • Dec 14Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% PoundingThe ProQR Therapeutics N.V. ( NASDAQ:PRQR ) share price has softened a substantial 29% over the previous 30 days...Buy Or Sell Opportunity • Dec 10Now 20% undervaluedOver the last 90 days, the stock has risen 79% to US$3.31. The fair value is estimated to be US$4.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 69% over the last 3 years. Earnings per share has grown by 41%. For the next 3 years, revenue is forecast to grow by 32% per annum. Earnings are forecast to decline by 3.3% per annum over the same time period.お知らせ • Dec 10ProQR Therapeutics N.V. Appoints Peter A. Beal, Phd, as Chief Adar ScientistProQR Therapeutics N.V. announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR’s Scientific Advisory Board, where he has played an important role in shaping the Company’s ADAR-based RNA editing platform.Dr. Beal’s decades of research at UC Davis have advanced the scientific community’s understanding of ADAR-mediated RNA-editing mechanisms and their therapeutic potential. As Chief ADAR Scientist, Dr. Beal will expand on his existing contributions to ProQR by driving the development and optimization of the Company’s ADAR editing platform, which aims to deliver life-changing treatments for patients with high unmet needs. In his new role, Dr. Beal will oversee the platform optimization and scientific developments on the design of editing oligonucleotides to further strengthen ProQR’s position as a leader in ADAR mediated RNA-editing innovation, drive preclinical development efforts, and expand the Company’s therapeutic pipeline. Peter A. Beal is a Professor in the Department of Chemistry at the University of California at Davis and current Director of the NIH-funded UC Davis Chemical Biology Graduate Program. Research from the Beal laboratory has advanced understanding of the structures and mechanism of action for ADAR enzymes responsible for adenosine to inosine RNA editing in humans. Recently, this knowledge has been applied to the design of guiding oligonucleotides capable of directing ADARs to make edits that correct disease-causing mutations in the transcriptome. Targets include mutations in mRNAs associated with Rett syndrome, Alzheimer’s disease and Parkinson’s disease. Dr. Beal teaches organic chemistry at the undergraduate level and several classes in nucleic acids chemistry and chemical biology at the graduate level.Price Target Changed • Dec 05Price target increased by 14% to US$8.00Up from US$7.03, the current price target is an average from 5 analysts. New target price is 126% above last closing price of US$3.54. Stock is up 74% over the past year. The company is forecast to post a net loss per share of €0.31 next year compared to a net loss per share of €0.35 last year.Reported Earnings • Nov 08Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: €0.099 loss per share (further deteriorated from €0.07 loss in 3Q 2023). Revenue: €3.98m (up 191% from 3Q 2023). Net loss: €8.11m (loss widened 42% from 3Q 2023). Revenue missed analyst estimates by 66%. Earnings per share (EPS) exceeded analyst estimates by 2.6%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Price Target Changed • Oct 29Price target increased by 40% to US$5.73Up from US$4.10, the current price target is an average from 5 analysts. New target price is 66% above last closing price of US$3.45. Stock is up 200% over the past year. The company is forecast to post a net loss per share of €0.31 next year compared to a net loss per share of €0.35 last year.お知らせ • Oct 24ProQR Therapeutics N.V. has completed a Follow-on Equity Offering in the amount of $63 million.ProQR Therapeutics N.V. has completed a Follow-on Equity Offering in the amount of $63 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 18,000,000 Price\Range: $3.5 Discount Per Security: $0.21分析記事 • Oct 23There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price JumpThe ProQR Therapeutics N.V. ( NASDAQ:PRQR ) share price has done very well over the last month, posting an excellent...お知らせ • Oct 23ProQR Therapeutics N.V. has filed a Follow-on Equity Offering.ProQR Therapeutics N.V. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stockお知らせ • Oct 01ProQR Therapeutics N.V. has filed a Follow-on Equity Offering in the amount of $75 million.ProQR Therapeutics N.V. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market OfferingMajor Estimate Revision • Aug 28Consensus revenue estimates increase by 35%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €18.2m to €24.5m. EPS estimate unchanged from -€0.31 at last update. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target broadly unchanged at US$4.13. Share price fell 5.7% to US$1.98 over the past week.Reported Earnings • Aug 09Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2024 results: €0.033 loss per share (improved from €0.099 loss in 2Q 2023). Revenue: €6.46m (up 420% from 2Q 2023). Net loss: €2.69m (loss narrowed 66% from 2Q 2023). Revenue missed analyst estimates by 37%. Earnings per share (EPS) exceeded analyst estimates by 72%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.分析記事 • Jul 15ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than ExpectedIt's not a stretch to say that ProQR Therapeutics N.V.'s ( NASDAQ:PRQR ) price-to-sales (or "P/S") ratio of 13.1x right...分析記事 • May 29Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging HigherProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders will have a reason to smile today, with the analysts making...Major Estimate Revision • May 24Consensus revenue estimates increase by 28%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €16.7m to €21.3m. EPS estimate unchanged from -€0.40 at last update. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target of US$4.10 unchanged from last update. Share price fell 3.1% to US$1.88 over the past week.お知らせ • May 09ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic DiseasesProQR Therapeutics NV announced new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical proof of concept data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP. The data are being presented at a poster session on May 8, 2024 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland. Preclinical proof of concept for AX-0810: AX-0810 is an editing oligonucleotide (EON) development program targeting the SLC10A1 RNA using the Axiomer technology, providing a transient and controlled approach that aims to reduce bile acids concentration in the liver. By specifically affecting the main transporter for bile acids reuptake from the portal vein circulation to the liver, called NTCP (Na-taurocholate transporting polypeptide, SLC10A1 gene), the AX-0810 program represents a promising avenue to ameliorate the progression of cholestatic disorders. As reported [ASGCT 2024, P-705], modulation of NTCP at different levels of editing leads to an increase in the biomarker Total Bile Acid in serum. Data presented include: Axiomer EONs can specifically modulate NTCP protein bile acids reuptake function while preserving expression of the protein. A strong correlation (R2 = 0.51) was reported between editing levels of NTCP and bile acids change in the serum in NHP in vivo. An early generation of ProQR’s Axiomer editing oligonucleotides (EONs), EON1, yielded up to 29% editing of NTCP in the liver of non-human primates (NHPs) after a single dose and, importantly, this led to an 8-fold change in the serum biomarker bile acids 72 hours after treatment. Further optimizations for EONs targeting NTCP have enabled achievement of up to 60% editing (in vitro). Results reported in NHPs confirmed findings in vitro models and showed translatability across models. ProQR is developing its AX-0810 program targeting NTCP for Cholestatic Diseases and plans to advance the program to the clinic in late 2024/early 2025. ProQR also expects the following Axiomer pipeline program milestones in 2024: AX-0810 clinical development candidate translational data to be reported in H2 2024, with further detail on design for the clinical trial. AX-1412 preclinical proof of concept data and translational data to be reported in H2 2024, with program to advance to the clinic in late 2024/early 2025. AX-1412 is the Company’s Axiomer program targeting B4GALT1 for cardiovascular disease.お知らせ • Apr 24ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024, at 16:30 Central European Standard Time. Location: the offices of Allen & Overy LLP, Apollolaan 15, 1077 AB in Amsterdam,the Netherlands Amsterdam Netherlands Agenda: To consider Report of the Management Board for the financial year 2023 ; to Adoption of the annual accounts for the financial year 2023; to Release from liability of the members of the Management Board with respect to the performance of their management during the financial year 2023 ; to Release from liability of the members of the Supervisory Board with respect to the performance of their supervision during the financial year 2023 ; to Appointment of Gerard Platenburg as Management Board member ; to Appointment of Martin Maier, PhD, as Supervisory Board member ; to Re-appointment of Dinko Valerio, PhD, as Supervisory Board member ; and to consider other matters if any.お知らせ • Apr 21ProQR Therapeutics N.V. Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioProQR Therapeutics N.V. announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™?. The opposition was filed in June 2021 with the European Patent Office (EPO) by a strawman against ProQR's granted patent EP 3 507 366 B1, which relates to editing oligonucleotides that have certain chemical modifications in the base and/or ribose sugar to increase stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR's intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules. The opposition Division of the EPO held a public meeting on April 17, 2024, and ruled such that ProQR's strong IP position on chemically modified editing oligonucleotides was maintained. The patent contains broad platform claims including: An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell--, which protects ProQR's proprietary ADAR mediated RNA editing platform Axiomer. ProQR invented the use of endogenous ADAR in RNA editing in 2014 and filed a first patent application in that same year. Since then, ProQR has filed multiple additional patent applications on further improvements to form a leading patent estate that supports ProQR’s ADAR-mediated RNA editing platform Axiomer. Today ProQR has extensive patent protection related to the Axiomer RNA editing platform, including 15 published patent families, that currently comprise a total of 28 patents. Beyond this, ProQR has several unpublished patent applications and continuously invests in expanding its IP estate around ADAR-mediated RNA editing.分析記事 • Apr 03Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Mar 20Consensus revenue estimates increase by 64%, EPS downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €11.1m to €18.3m. EPS estimate fell from -€0.351 to -€0.409 per share. Biotechs industry in the US expected to see average net income decline 8.2% next year. Consensus price target up from US$3.88 to US$4.06. Share price rose 6.0% to US$2.47 over the past week.Reported Earnings • Mar 14Third quarter 2023 earnings released: €0.07 loss per share (vs €0.33 loss in 3Q 2022)Third quarter 2023 results: €0.07 loss per share (improved from €0.33 loss in 3Q 2022). Net loss: €5.71m (loss narrowed 76% from 3Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 4 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.New Risk • Mar 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€40m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding).Major Estimate Revision • Dec 22Consensus revenue estimates increase by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €16.0m to €17.8m. EPS estimate unchanged from -€0.24 at last update. Biotechs industry in the US expected to see average net income growth of 7.6% next year. Consensus price target of US$3.88 unchanged from last update. Share price was steady at US$2.01 over the past week.New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.6% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€36m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding).分析記事 • Nov 28Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Nov 09Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: €0.07 loss per share (improved from €0.34 loss in 3Q 2022). Net loss: €5.71m (loss narrowed 77% from 3Q 2022). Revenue missed analyst estimates by 60%. Earnings per share (EPS) exceeded analyst estimates by 14%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€35m net loss in 3 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (€4.5m revenue, or US$4.8m). Market cap is less than US$100m (US$98.7m market cap).New Risk • Oct 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€32m net loss in 3 years). Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (€4.5m revenue, or US$4.8m). Market cap is less than US$100m (US$98.7m market cap).Major Estimate Revision • Sep 28Consensus revenue estimates increase by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €18.7m to €21.5m. EPS estimate unchanged from -€0.27 at last update. Biotechs industry in the US expected to see average net income decline 4.0% next year. Consensus price target of US$3.76 unchanged from last update. Share price fell 10% to US$1.33 over the past week.Major Estimate Revision • Aug 10Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €23.8m to €19.9m. Forecast losses increased from -€0.238 to -€0.262 per share. Biotechs industry in the US expected to see average net income decline 20% next year. Consensus price target of US$3.80 unchanged from last update. Share price was steady at US$1.49 over the past week.New Risk • Aug 07New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.9% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€37m net loss in 3 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (€4.5m revenue, or US$4.9m).Reported Earnings • Aug 04Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: €0.099 loss per share (improved from €0.21 loss in 2Q 2022). Net loss: €7.99m (loss narrowed 46% from 2Q 2022). Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is expected to decline by 10% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • Aug 03Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €135 million.Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €135 million on July 31, 2023. Based on the terms and agreements ProQR will receive an initial payment of €12.5 million and will also be eligible to receive up to €135 million in further development, regulatory, and commercial payments as well as additional earn outs of up to high. teens percentage based on commercial sales in the United States and the European Union. The transaction is subject to the satisfaction of certain closing conditions and covenants. The transaction is expected to close in the third quarter of 2023. Lazard B.V. acted as financial advisor and Allen & Overy Amsterdam acted as legal advisor to ProQR Therapeutics. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor to Laboratoires Théa.分析記事 • Jul 30Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Major Estimate Revision • May 27Consensus revenue estimates decrease by 25%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €26.7m to €20.0m. EPS estimate unchanged at -€0.243 per share. Biotechs industry in the US expected to see average net income decline 82% next year. Consensus price target of US$3.80 unchanged from last update. Share price fell 8.8% to US$1.72 over the past week.Major Estimate Revision • May 26Consensus EPS estimates upgraded to €0.24 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €27.2m to €24.5m. 2023 losses expected to reduce from -€0.508 to -€0.243 per share. Biotechs industry in the US expected to see average net income decline 82% next year. Consensus price target of US$3.82 unchanged from last update. Share price fell 4.0% to US$1.67 over the past week.Price Target Changed • May 25Price target decreased by 9.2% to US$3.82Down from US$4.21, the current price target is an average from 7 analysts. New target price is 117% above last closing price of US$1.76. Stock is up 181% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €0.91 last year.お知らせ • May 18ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board MemberOn May 17, 2023, ProQR Therapeutics N.V. held its 2023 annual general meeting of shareholders. ProQR shareholders approved the appointment of Theresa Heggie and Begoña Carreño as Supervisory Board member.Reported Earnings • May 18First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2023 results: €0.11 loss per share (improved from €0.20 loss in 1Q 2022). Net loss: €8.93m (loss narrowed 38% from 1Q 2022). Revenue missed analyst estimates by 47%. Earnings per share (EPS) exceeded analyst estimates by 7.5%. Revenue is expected to decline by 34% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Breakeven Date Change • May 17Forecast to breakeven in 2023The 4 analysts covering ProQR Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €6.73m in 2023.Reported Earnings • Mar 31Full year 2022 earnings: EPS in line with expectations, revenues disappointFull year 2022 results: €0.91 loss per share. Net loss: €65.1m (loss widened 5.7% from FY 2021). Revenue missed analyst estimates by 66%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 13% growth forecast for the Biotechs industry in the US.分析記事 • Mar 17Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Price Target Changed • Dec 23Price target increased to US$3.25Up from US$1.72, the current price target is an average from 6 analysts. New target price is 20% above last closing price of US$2.71. Stock is down 67% over the past year. The company is forecast to post a net loss per share of €0.92 next year compared to a net loss per share of €0.96 last year.Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €3.98m to €4.20m. Forecast EPS reduced from -€0.80 to -€0.94 per share. Biotechs industry in the US expected to see average net income decline 93% next year. Consensus price target of US$1.72 unchanged from last update. Share price rose 3.4% to US$0.96 over the past week.Reported Earnings • Nov 11Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: €0.34 loss per share (further deteriorated from €0.22 loss in 3Q 2021). Net loss: €24.4m (loss widened 62% from 3Q 2021). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) missed analyst estimates by 63%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.Major Estimate Revision • Aug 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €4.73m to €4.25m. EPS estimate increased from -€0.86 to -€0.78 per share. Biotechs industry in the US expected to see average net income decline 77% next year. Consensus price target down from US$2.53 to US$1.80. Share price rose 7.6% to US$0.89 over the past week.Major Estimate Revision • Aug 11Consensus revenue estimates increase by 25%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from €3.63m to €4.55m. Forecast losses expected to reduce from -€0.86 to -€0.81 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target of US$2.42 unchanged from last update. Share price fell 3.6% to US$0.81 over the past week.Seeking Alpha • Aug 11ProQR says EU regulator seeks additional trial for lead candidateDutch biotech ProQR Therapeutics N.V. (NASDAQ:PRQR) announced on Thursday that the European Medicines Agency (EMA) recommended an additional pivotal clinical trial before submitting a marketing application for the company’s lead candidate sepofarsen. An investigational RNA therapy, sepofarsen, is designed to target Leber congenital amaurosis 10, a common cause of blindness due to genetic factors in children. Following the EMA feedback, ProQR (PRQR) has decided to look for a strategic partner to further advance its ophthalmology portfolio, which also includes RNA candidate ultevursen (QR-421a) targeted at Usher syndrome and retinitis pigmentosa. Until a partnership is formed and to preserve capital, the company will terminate the ongoing trials for sepofarsen and ultevursen, including Illuminate, Insight, and Brighten studies for sepofarsen, along with Sirius and Helia trials for ultevursen. In addition, ProQR (PRQR) announced a workforce reduction which it said will help extend the cash runway into 2026, along with the decision to wind down trials for sepofarsen and ultevursen. Early this year, the company announced that its pivotal Phase 2/3 study for sepofarsen did not meet the main goal in LCA10.Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: €0.21 loss per share (up from €0.24 loss in 2Q 2021). Net loss: €14.9m (loss narrowed 5.5% from 2Q 2021). Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 8.0%. Over the next year, revenue is expected to shrink by 5.7% compared to a 46% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.Major Estimate Revision • May 12Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €3.20m to €3.49m. EPS estimate increased from -€0.92 per share to -€0.82 per share. Biotechs industry in the US expected to see average net income decline 44% next year. Consensus price target down from US$3.17 to US$2.42. Share price fell 20% to US$0.56 over the past week.Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: €0.20 loss per share. Net loss: €14.4m (loss widened 15% from 1Q 2021). Revenue exceeded analyst estimates by 59%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is expected to shrink by 4.8% compared to a 41% growth forecast for the industry in the US.Price Target Changed • Apr 27Price target decreased to US$3.29Down from US$4.86, the current price target is an average from 6 analysts. New target price is 344% above last closing price of US$0.74. Stock is down 88% over the past year. The company is forecast to post a net loss per share of €0.85 next year compared to a net loss per share of €0.96 last year.Price Target Changed • Apr 14Price target decreased to US$3.64Down from US$4.96, the current price target is an average from 6 analysts. New target price is 363% above last closing price of US$0.79. Stock is down 87% over the past year. The company is forecast to post a net loss per share of €0.88 next year compared to a net loss per share of €0.96 last year.Reported Earnings • Feb 26Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.96 loss per share (down from €0.93 loss in FY 2020). Net loss: €61.6m (loss widened 32% from FY 2020). Revenue missed analyst estimates by 52%. Earnings per share (EPS) exceeded analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 42%, compared to a 185% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.Price Target Changed • Feb 13Price target decreased to US$13.50Down from US$24.13, the current price target is an average from 7 analysts. New target price is 871% above last closing price of US$1.39. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.97 next year compared to a net loss per share of €0.93 last year.分析記事 • Nov 10Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing MoneyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Oct 01Investment Case On ProQR Therapeutics Gets More EnticingToday, we revisit ProQR Therapeutics, an intriguing developmental concern for the first time since early this year. The company recently inked a significant collaboration deal with drug giant Eli Lilly which makes its investment case more enticing. We update the investment thesis on ProQR Therapeutics to account for recent events in the paragraphs below.Major Estimate Revision • Aug 06Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €561.2k to €449.9k. EPS estimate unchanged from -€0.82 per share at last update. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$26.00 unchanged from last update. Share price rose 20% to US$6.26 over the past week.分析記事 • Aug 04ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • May 13It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This YearCEO Daniel de Boer has done a decent job of delivering relatively good performance at ProQR Therapeutics N.V...Major Estimate Revision • May 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €1.66m to €1.19m. EPS estimate increased from -€1.02 to -€0.93 per share. Biotechs industry in the US expected to see average net income decline 15% next year. Consensus price target down from US$28.33 to US$26.57. Share price rose 2.1% to US$6.32 over the past week.Price Target Changed • Mar 25Price target increased to US$24.17Up from US$21.50, the current price target is an average from 4 analysts. New target price is 325% above last closing price of US$5.68. Stock is down 4.5% over the past year.業績と収益の成長予測NasdaqCM:PRQR - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202872-5013-28312/31/202714-71-95-85612/31/202613-58N/A-5763/31/202614-45-49-48N/A12/31/202516-42-54-53N/A9/30/202516-43-49-49N/A6/30/202517-40-43-42N/A3/31/202520-30-38-37N/A12/31/202420-28-38-36N/A9/30/202418-24-26-32N/A6/30/202416-22-28-34N/A3/31/202411-27-32-38N/A12/31/20237-282822N/A9/30/20235-3689N/A6/30/20234-5411N/A3/31/20234-59-4-3N/A12/31/20224-64-69-69N/A9/30/20224-69-48-47N/A6/30/20224-61-40-40N/A3/31/20223-63-35-35N/A12/31/20212-61-26-26N/A9/30/20212-57-42-42N/A6/30/20212-55-44-43N/A3/31/20211-43-45-44N/A12/31/20201-47-48-47N/A9/30/20201-52-48-47N/A6/30/20201-51-47-46N/A3/31/20202-58-47-47N/A12/31/20192-56N/A-44N/A9/30/20193-51N/A-41N/A6/30/20195-45N/A-37N/A3/31/20196-40N/A-31N/A12/31/20186-37N/A-28N/A9/30/20184-35N/A-28N/A6/30/20182-40N/A-31N/A3/31/20181-44N/A-36N/A12/31/20171-44N/A-35N/A9/30/20171-41N/A-34N/A6/30/20171-41N/A-37N/A3/31/20171-39N/A-35N/A12/31/20162-39N/A-34N/A9/30/20163-36N/A-34N/A6/30/20163-33N/A-29N/A3/31/20163-31N/A-27N/A12/31/20153-21N/A-24N/A9/30/20153-17N/A-22N/A6/30/20151-14N/A-20N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PRQR今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PRQR今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: PRQR今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: PRQRの収益 ( 49% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: PRQRの収益 ( 49% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PRQRの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 11:45終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋ProQR Therapeutics N.V. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19 アナリスト機関Douglas BuchananBrean Capital Historical (Janney Montgomery)Eliana MerleCantor Fitzgerald & Co.Steven SeedhouseCantor Fitzgerald & Co.16 その他のアナリストを表示
Major Estimate Revision • May 13Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €19.4m to €15.2m. Forecast losses increased from -€0.505 to -€0.525 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$8.88 unchanged from last update. Share price was steady at US$1.70 over the past week.
Major Estimate Revision • Mar 19Consensus revenue estimates increase by 11%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from €17.7m to €19.5m. Forecast losses expected to reduce from -€0.539 to -€0.487 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$8.88 unchanged from last update. Share price fell 7.6% to US$1.59 over the past week.
Major Estimate Revision • Nov 13Consensus revenue estimates decrease by 19%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €20.1m to €16.3m. EPS estimate unchanged from -€0.42 per share at last update. Biotechs industry in the US expected to see average net income decline 9.7% next year. Consensus price target of US$8.88 unchanged from last update. Share price fell 9.2% to US$2.16 over the past week.
Price Target Changed • May 14Price target decreased by 7.8% to US$8.88Down from US$9.63, the current price target is an average from 8 analysts. New target price is 473% above last closing price of US$1.55. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.32 last year.
Price Target Changed • Mar 30Price target increased by 13% to US$10.67Up from US$9.43, the current price target is an average from 6 analysts. New target price is 662% above last closing price of US$1.40. Stock is down 39% over the past year. The company is forecast to post a net loss per share of €0.39 next year compared to a net loss per share of €0.32 last year.
Major Estimate Revision • Mar 20Consensus revenue estimates increase by 12%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €13.7m to €15.3m. EPS estimate fell from -€0.369 to -€0.394 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$9.43 to US$9.71. Share price fell 12% to US$1.63 over the past week.
Reported Earnings • May 14First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: €0.13 loss per share (further deteriorated from €0.096 loss in 1Q 2025). Revenue: €2.03m (down 57% from 1Q 2025). Net loss: €13.4m (loss widened 33% from 1Q 2025). Revenue missed analyst estimates by 61%. Earnings per share (EPS) also missed analyst estimates by 9.2%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 13Consensus revenue estimates fall by 22%The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €19.4m to €15.2m. Forecast losses increased from -€0.505 to -€0.525 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$8.88 unchanged from last update. Share price was steady at US$1.70 over the past week.
お知らせ • May 06ProQR Therapeutics N.V., Annual General Meeting, Jun 02, 2026ProQR Therapeutics N.V., Annual General Meeting, Jun 02, 2026. Location: allen overy shearman sterling llp, apollolaan 15, 1077, ab in amsterdam, netherlands, amsterdam Netherlands
New Risk • Apr 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€43m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).
お知らせ • Apr 08ProQR Therapeutics N.V. Establishes AI Advisory BoardProQR Therapeutics N.V. has established an AI Advisory Board comprising leaders from the AI and techbio fields to support the development of the Company’s AI strategy for Axiomer. Members of the ProQR AI Advisory Board include: Eric Durand, PhD, Chief Data Science Officer, Owkin; David Ruau, PhD, Head of BD EMEA, Healthcare & Life Sciences, NVIDIA; Thomas Wolf, Co-Founder and Chief Science Officer of Hugging Face; Gerard van Westen, Full Professor AI and Medicinal Chemistry at Leiden University; Romain Lacombe, Venture Partner, HCVC; Imran Haque, PhD, Chief Technology Officer, Kimia Therapeutics.
Major Estimate Revision • Mar 19Consensus revenue estimates increase by 11%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from €17.7m to €19.5m. Forecast losses expected to reduce from -€0.539 to -€0.487 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$8.88 unchanged from last update. Share price fell 7.6% to US$1.59 over the past week.
Board Change • Mar 17High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 3 experienced directors. 1 highly experienced director. Member of Scientific Advisory Board Phil Zamore is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Mar 13Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2025 results: €0.40 loss per share (further deteriorated from €0.32 loss in FY 2024). Revenue: €16.3m (down 16% from FY 2024). Net loss: €42.2m (loss widened 52% from FY 2024). Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) exceeded analyst estimates by 5.0%. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
お知らせ • Feb 10ProQR Therapeutics N.V. Announces Planned Changes to Board CompositionProQR Therapeutics N.V. announced that Dinko Valerio, a co-founder of the Company, and Alison Lawton will rotate off the Board at the Company’s next Annual General Meeting (AGM) as their terms conclude. The planned changes to ProQR’s Board composition at its 2026 AGM reflect the Company’s development as it advances its clinical programs, as well as its ongoing commitment to strong corporate governance and long-term succession planning. An executive search firm has been engaged to assist ProQR in identifying candidates to be nominated to the Board to support long-term value creation for all its stakeholders. As part of its ongoing governance practices, the Board regularly reviews its composition to ensure it maintains an appropriate balance of skills, experience, and perspectives to support ProQR’s long-term strategic objectives. This process has resulted in the appointment of two new Board members in the last three years.
分析記事 • Jan 13Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price PlungeTo the annoyance of some shareholders, ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shares are down a considerable 28% in...
お知らせ • Jan 08Proqr Therapeutics N.V. Announces Encouraging Ax-0810 Phase 1 Safety and Pk Data, Development Candidate SelectionsProQR Therapeutics N.V. announced encouraging initial safety and PK data from the first cohort of healthy volunteers in its ongoing Phase 1 trial of AX-0810 and provided an update on broader pipeline progress and anticipated 2026 milestones. The ongoing Phase 1 study of AX-0810 is a single-center, randomized, double-blind, placebo-controlled, multiple dose escalation study being conducted in healthy volunteers in the Netherlands. Up to 33 participants will be enrolled, including 24 receiving AX-0810 and 9 receiving placebo, across 3 dose cohorts. Participants receive 4 subcutaneous injections over 4 weeks followed by a 12-week safety follow-up period. A Data Monitoring Committee reviews safety data prior to each dose escalation. The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics (PK) of AX-0810 and to confirm target engagement as measured by biomarkers (EUCT number: 2025-521876-77-00).: Based on initial 4-week safety and PK data from participants dosed in Cohort 1 (3mg/kg), AX-0810 demonstrated a safety profile with no serious adverse events or clinically meaningful laboratory abnormalities observed to date. Preliminary pharmacokinetic observations are in line with non-clinical data, supporting continued dosing per the study design. ProQR remains on track to report target engagement data for healthy volunteer cohorts in the first half of 2026. In parallel, activities are underway to include a patient cohort in this Phase 1 first-in-human trial following the healthy volunteer cohorts. In addition to AX-0810, ProQR continues to advance earlier-stage pipeline programs from its Axiomer RNA editing platform, with Development Candidates selected for pipeline programs AX-2402 and AX-2911. AX-2402 is the Company’s development program targeting MECP2 for Rett syndrome (R270X). ProQR selected a Development Candidate for AX-2402 based on a robust preclinical profile supporting advancement to development activities, with the objective of initiating a first-in-human clinical trial in the first half of 2027. ProQR also announced non-clinical proof-of-concept data generated in a mouse model of Rett syndrome with the MECP2 R270X mutation. Treatment with AX-2402 resulted in statistically significant and clinically relevant functional improvements. These effects included improvement in cumulative Bird score, driven in part by robust improvements in hindlimb clasping score. Further details and analyses will be presented at a later date. AX-2402 is supported by funding of up to $9.2M from the Rett Syndrome Research Trust (RSRT).
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€51m net loss in 3 years). Share price has been volatile over the past 3 months (11% average weekly change).
分析記事 • Nov 24ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 29% Share Price Plunge Could Signal Some RiskProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders won't be pleased to see that the share price has had a very rough...
Major Estimate Revision • Nov 13Consensus revenue estimates decrease by 19%The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €20.1m to €16.3m. EPS estimate unchanged from -€0.42 per share at last update. Biotechs industry in the US expected to see average net income decline 9.7% next year. Consensus price target of US$8.88 unchanged from last update. Share price fell 9.2% to US$2.16 over the past week.
Reported Earnings • Nov 07Third quarter 2025 earnings released: €0.10 loss per share (vs €0.099 loss in 3Q 2024)Third quarter 2025 results: €0.10 loss per share (further deteriorated from €0.099 loss in 3Q 2024). Revenue: €2.92m (down 27% from 3Q 2024). Net loss: €11.0m (loss widened 36% from 3Q 2024). Revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 34% per year, which means it is significantly lagging earnings growth.
分析記事 • Nov 05Is ProQR Therapeutics (NASDAQ:PRQR) Using Debt Sensibly?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Oct 21ProQR Therapeutics N.V. Receives CTA Authorization for AX-0810ProQR Therapeutics N.V. announced that following review under the new European Medicines Agency (EMA) centralized review process, the Central Committee on Research Involving Human Subjects (CCMO) has authorized ProQR’s Clinical Trial Application (CTA) for a Phase 1 study of AX-0810 in healthy volunteers. AX-0810 is the Company’s lead investigational editing oligonucleotide (EON) targeting NTCP, which is being developed for the treatment of cholestatic diseases like primary sclerosing cholangitis and biliary atresia. With this CTA approval, ProQR is authorized to begin dosing in its Phase 1 study, which is being conducted in the Netherlands. The Phase 1 study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) via biomarkers to establish proof of target engagement. AX-0810 is a first-in-class investigational RNA editing oligonucleotide (EON) that harnesses the body’s endogenous ADAR enzymes to selectively modulate NTCP function. Through this novel mechanism, AX-0810 aims to reduce toxic bile acid accumulation in the liver and improve outcomes in cholestatic diseases, which are characterized by inflammation, fibrosis, and progressive liver failure. By targeting a key pathogenic process that drives disease progression, AX-0810 has the potential to be disease-modifying. AX-0810 is the first program from ProQR’s Axiomer™ RNA editing pipeline to enter clinical development and is being evaluated in a Phase 1 trial in healthy volunteers focused on safety, pharmacokinetics, and biomarkers of target engagement to inform future studies in patients.
分析記事 • Oct 10ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Price Is Out Of Tune With RevenuesYou may think that with a price-to-sales (or "P/S") ratio of 13.3x ProQR Therapeutics N.V. ( NASDAQ:PRQR ) is a stock...
Reported Earnings • Aug 08Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: €0.12 loss per share (further deteriorated from €0.033 loss in 2Q 2024). Revenue: €3.98m (down 39% from 2Q 2024). Net loss: €12.2m (loss widened 352% from 2Q 2024). Revenue missed analyst estimates by 7.7%. Earnings per share (EPS) also missed analyst estimates by 50%. Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.
お知らせ • Jun 27Proqr Announces Cta Submission for Phase 1 Study of Ax-0810 Targeting NtcpProQR Therapeutics NV announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases. Axiomer "Editing Oligonucleotides", or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA - an Inosine is translated as a Guanosine (G) - correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease.
分析記事 • Jun 13ProQR Therapeutics N.V. (NASDAQ:PRQR) Stock Rockets 27% As Investors Are Less Pessimistic Than ExpectedProQR Therapeutics N.V. ( NASDAQ:PRQR ) shares have had a really impressive month, gaining 27% after a shaky period...
分析記事 • May 27Here's Why ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO May Deserve A RaiseKey Insights ProQR Therapeutics' Annual General Meeting to take place on 3rd of June CEO Daniel de Boer's total...
Price Target Changed • May 14Price target decreased by 7.8% to US$8.88Down from US$9.63, the current price target is an average from 8 analysts. New target price is 473% above last closing price of US$1.55. Stock is down 19% over the past year. The company is forecast to post a net loss per share of €0.38 next year compared to a net loss per share of €0.32 last year.
分析記事 • May 09New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)Celebrations may be in order for ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders, with the analysts delivering a...
Reported Earnings • May 09First quarter 2025 earnings released: €0.096 loss per share (vs €0.094 loss in 1Q 2024)First quarter 2025 results: €0.096 loss per share (further deteriorated from €0.094 loss in 1Q 2024). Revenue: €4.74m (up 1.7% from 1Q 2024). Net loss: €10.1m (loss widened 32% from 1Q 2024). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth.
New Risk • May 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€63m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding).
お知らせ • May 02ProQR Therapeutics N.V., Annual General Meeting, Jun 03, 2025ProQR Therapeutics N.V., Annual General Meeting, Jun 03, 2025. Location: 1530 cest at the offices, allen overy shearman sterling llp, amsterdam Netherlands
分析記事 • Apr 14ProQR Therapeutics N.V. (NASDAQ:PRQR) Not Doing Enough For Some Investors As Its Shares Slump 34%To the annoyance of some shareholders, ProQR Therapeutics N.V. ( NASDAQ:PRQR ) shares are down a considerable 34% in...
お知らせ • Apr 14+ 1 more updateProQR Therapeutics N.V. Announces Chief Financial Officer ChangesProQR Therapeutics NV. announced the appointment of Dennis Hom as Chief Financial Officer (CFO). The key leadership appointment support the advancement of the Company’s Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage. Dennis Hom, most recently CFO and Head of Corporate Development at Sagimet Biosciences, brings over 25 years of financial leadership across public and private biotech companies. He has raised more than $4.5 billion in capital and executed transactions totaling over $57 billion in disclosed value. At Sagimet, he led multiple financings, including its IPO, and executed a transformational licensing transaction. Earlier in his career, Mr. Hom held roles in business development and M&A at Amgen and Novartis, following investment banking experience at Hambrecht & Quist and its mergers with Chase and JP Morgan, where he advised biotech companies on capital strategy and M&A. He holds a bachelor's degree in biology from the Massachusetts Institute of Technology, where he conducted research in the lab of Nobel Laureate H. Robert Horvitz. At ProQR, Mr. Hom will oversee all corporate development functions, including corporate finance, investor relations, and business development. Chief Financial Officer Jurriaan Dekkers will be stepping down from their roles, having played key roles in supporting the Company’s strategic transition to a focused RNA editing platform. The executive will remain with the Company during a transitional period to ensure continuity.
Price Target Changed • Mar 30Price target increased by 13% to US$10.67Up from US$9.43, the current price target is an average from 6 analysts. New target price is 662% above last closing price of US$1.40. Stock is down 39% over the past year. The company is forecast to post a net loss per share of €0.39 next year compared to a net loss per share of €0.32 last year.
Major Estimate Revision • Mar 20Consensus revenue estimates increase by 12%, EPS downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €13.7m to €15.3m. EPS estimate fell from -€0.369 to -€0.394 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$9.43 to US$9.71. Share price fell 12% to US$1.63 over the past week.
Reported Earnings • Mar 13Full year 2024 earnings: EPS and revenues miss analyst expectationsFull year 2024 results: €0.32 loss per share (improved from €0.35 loss in FY 2023). Revenue: €19.5m (up 196% from FY 2023). Net loss: €27.8m (loss narrowed 1.3% from FY 2023). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) also missed analyst estimates by 7.3%. Revenue is forecast to grow 41% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 44% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth.
分析記事 • Dec 14Some ProQR Therapeutics N.V. (NASDAQ:PRQR) Shareholders Look For Exit As Shares Take 29% PoundingThe ProQR Therapeutics N.V. ( NASDAQ:PRQR ) share price has softened a substantial 29% over the previous 30 days...
Buy Or Sell Opportunity • Dec 10Now 20% undervaluedOver the last 90 days, the stock has risen 79% to US$3.31. The fair value is estimated to be US$4.16, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 69% over the last 3 years. Earnings per share has grown by 41%. For the next 3 years, revenue is forecast to grow by 32% per annum. Earnings are forecast to decline by 3.3% per annum over the same time period.
お知らせ • Dec 10ProQR Therapeutics N.V. Appoints Peter A. Beal, Phd, as Chief Adar ScientistProQR Therapeutics N.V. announced the appointment of Dr. Peter Beal, a professor of Chemistry at the University of California, Davis, as Chief ADAR Scientist. Dr. Beal, one of the top experts in ADAR and RNA biology and chemistry, has been a long-term collaborator of ProQR and a valued member of ProQR’s Scientific Advisory Board, where he has played an important role in shaping the Company’s ADAR-based RNA editing platform.Dr. Beal’s decades of research at UC Davis have advanced the scientific community’s understanding of ADAR-mediated RNA-editing mechanisms and their therapeutic potential. As Chief ADAR Scientist, Dr. Beal will expand on his existing contributions to ProQR by driving the development and optimization of the Company’s ADAR editing platform, which aims to deliver life-changing treatments for patients with high unmet needs. In his new role, Dr. Beal will oversee the platform optimization and scientific developments on the design of editing oligonucleotides to further strengthen ProQR’s position as a leader in ADAR mediated RNA-editing innovation, drive preclinical development efforts, and expand the Company’s therapeutic pipeline. Peter A. Beal is a Professor in the Department of Chemistry at the University of California at Davis and current Director of the NIH-funded UC Davis Chemical Biology Graduate Program. Research from the Beal laboratory has advanced understanding of the structures and mechanism of action for ADAR enzymes responsible for adenosine to inosine RNA editing in humans. Recently, this knowledge has been applied to the design of guiding oligonucleotides capable of directing ADARs to make edits that correct disease-causing mutations in the transcriptome. Targets include mutations in mRNAs associated with Rett syndrome, Alzheimer’s disease and Parkinson’s disease. Dr. Beal teaches organic chemistry at the undergraduate level and several classes in nucleic acids chemistry and chemical biology at the graduate level.
Price Target Changed • Dec 05Price target increased by 14% to US$8.00Up from US$7.03, the current price target is an average from 5 analysts. New target price is 126% above last closing price of US$3.54. Stock is up 74% over the past year. The company is forecast to post a net loss per share of €0.31 next year compared to a net loss per share of €0.35 last year.
Reported Earnings • Nov 08Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2024 results: €0.099 loss per share (further deteriorated from €0.07 loss in 3Q 2023). Revenue: €3.98m (up 191% from 3Q 2023). Net loss: €8.11m (loss widened 42% from 3Q 2023). Revenue missed analyst estimates by 66%. Earnings per share (EPS) exceeded analyst estimates by 2.6%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Price Target Changed • Oct 29Price target increased by 40% to US$5.73Up from US$4.10, the current price target is an average from 5 analysts. New target price is 66% above last closing price of US$3.45. Stock is up 200% over the past year. The company is forecast to post a net loss per share of €0.31 next year compared to a net loss per share of €0.35 last year.
お知らせ • Oct 24ProQR Therapeutics N.V. has completed a Follow-on Equity Offering in the amount of $63 million.ProQR Therapeutics N.V. has completed a Follow-on Equity Offering in the amount of $63 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 18,000,000 Price\Range: $3.5 Discount Per Security: $0.21
分析記事 • Oct 23There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price JumpThe ProQR Therapeutics N.V. ( NASDAQ:PRQR ) share price has done very well over the last month, posting an excellent...
お知らせ • Oct 23ProQR Therapeutics N.V. has filed a Follow-on Equity Offering.ProQR Therapeutics N.V. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock
お知らせ • Oct 01ProQR Therapeutics N.V. has filed a Follow-on Equity Offering in the amount of $75 million.ProQR Therapeutics N.V. has filed a Follow-on Equity Offering in the amount of $75 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
Major Estimate Revision • Aug 28Consensus revenue estimates increase by 35%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €18.2m to €24.5m. EPS estimate unchanged from -€0.31 at last update. Biotechs industry in the US expected to see average net income decline 14% next year. Consensus price target broadly unchanged at US$4.13. Share price fell 5.7% to US$1.98 over the past week.
Reported Earnings • Aug 09Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2024 results: €0.033 loss per share (improved from €0.099 loss in 2Q 2023). Revenue: €6.46m (up 420% from 2Q 2023). Net loss: €2.69m (loss narrowed 66% from 2Q 2023). Revenue missed analyst estimates by 37%. Earnings per share (EPS) exceeded analyst estimates by 72%. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
分析記事 • Jul 15ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than ExpectedIt's not a stretch to say that ProQR Therapeutics N.V.'s ( NASDAQ:PRQR ) price-to-sales (or "P/S") ratio of 13.1x right...
分析記事 • May 29Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging HigherProQR Therapeutics N.V. ( NASDAQ:PRQR ) shareholders will have a reason to smile today, with the analysts making...
Major Estimate Revision • May 24Consensus revenue estimates increase by 28%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €16.7m to €21.3m. EPS estimate unchanged from -€0.40 at last update. Biotechs industry in the US expected to see average net income decline 10% next year. Consensus price target of US$4.10 unchanged from last update. Share price fell 3.1% to US$1.88 over the past week.
お知らせ • May 09ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic DiseasesProQR Therapeutics NV announced new preclinical data for its proprietary Axiomer™ RNA editing technology platform, including the first preclinical proof of concept data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP. The data are being presented at a poster session on May 8, 2024 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland. Preclinical proof of concept for AX-0810: AX-0810 is an editing oligonucleotide (EON) development program targeting the SLC10A1 RNA using the Axiomer technology, providing a transient and controlled approach that aims to reduce bile acids concentration in the liver. By specifically affecting the main transporter for bile acids reuptake from the portal vein circulation to the liver, called NTCP (Na-taurocholate transporting polypeptide, SLC10A1 gene), the AX-0810 program represents a promising avenue to ameliorate the progression of cholestatic disorders. As reported [ASGCT 2024, P-705], modulation of NTCP at different levels of editing leads to an increase in the biomarker Total Bile Acid in serum. Data presented include: Axiomer EONs can specifically modulate NTCP protein bile acids reuptake function while preserving expression of the protein. A strong correlation (R2 = 0.51) was reported between editing levels of NTCP and bile acids change in the serum in NHP in vivo. An early generation of ProQR’s Axiomer editing oligonucleotides (EONs), EON1, yielded up to 29% editing of NTCP in the liver of non-human primates (NHPs) after a single dose and, importantly, this led to an 8-fold change in the serum biomarker bile acids 72 hours after treatment. Further optimizations for EONs targeting NTCP have enabled achievement of up to 60% editing (in vitro). Results reported in NHPs confirmed findings in vitro models and showed translatability across models. ProQR is developing its AX-0810 program targeting NTCP for Cholestatic Diseases and plans to advance the program to the clinic in late 2024/early 2025. ProQR also expects the following Axiomer pipeline program milestones in 2024: AX-0810 clinical development candidate translational data to be reported in H2 2024, with further detail on design for the clinical trial. AX-1412 preclinical proof of concept data and translational data to be reported in H2 2024, with program to advance to the clinic in late 2024/early 2025. AX-1412 is the Company’s Axiomer program targeting B4GALT1 for cardiovascular disease.
お知らせ • Apr 24ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024ProQR Therapeutics N.V., Annual General Meeting, May 22, 2024, at 16:30 Central European Standard Time. Location: the offices of Allen & Overy LLP, Apollolaan 15, 1077 AB in Amsterdam,the Netherlands Amsterdam Netherlands Agenda: To consider Report of the Management Board for the financial year 2023 ; to Adoption of the annual accounts for the financial year 2023; to Release from liability of the members of the Management Board with respect to the performance of their management during the financial year 2023 ; to Release from liability of the members of the Supervisory Board with respect to the performance of their supervision during the financial year 2023 ; to Appointment of Gerard Platenburg as Management Board member ; to Appointment of Martin Maier, PhD, as Supervisory Board member ; to Re-appointment of Dinko Valerio, PhD, as Supervisory Board member ; and to consider other matters if any.
お知らせ • Apr 21ProQR Therapeutics N.V. Achieves Successful Defense of New Challenge to its Axiomer™ IP PortfolioProQR Therapeutics N.V. announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™?. The opposition was filed in June 2021 with the European Patent Office (EPO) by a strawman against ProQR's granted patent EP 3 507 366 B1, which relates to editing oligonucleotides that have certain chemical modifications in the base and/or ribose sugar to increase stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR's intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules. The opposition Division of the EPO held a public meeting on April 17, 2024, and ruled such that ProQR's strong IP position on chemically modified editing oligonucleotides was maintained. The patent contains broad platform claims including: An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell--, which protects ProQR's proprietary ADAR mediated RNA editing platform Axiomer. ProQR invented the use of endogenous ADAR in RNA editing in 2014 and filed a first patent application in that same year. Since then, ProQR has filed multiple additional patent applications on further improvements to form a leading patent estate that supports ProQR’s ADAR-mediated RNA editing platform Axiomer. Today ProQR has extensive patent protection related to the Axiomer RNA editing platform, including 15 published patent families, that currently comprise a total of 28 patents. Beyond this, ProQR has several unpublished patent applications and continuously invests in expanding its IP estate around ADAR-mediated RNA editing.
分析記事 • Apr 03Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Mar 20Consensus revenue estimates increase by 64%, EPS downgradedThe consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast increased from €11.1m to €18.3m. EPS estimate fell from -€0.351 to -€0.409 per share. Biotechs industry in the US expected to see average net income decline 8.2% next year. Consensus price target up from US$3.88 to US$4.06. Share price rose 6.0% to US$2.47 over the past week.
Reported Earnings • Mar 14Third quarter 2023 earnings released: €0.07 loss per share (vs €0.33 loss in 3Q 2022)Third quarter 2023 results: €0.07 loss per share (improved from €0.33 loss in 3Q 2022). Net loss: €5.71m (loss narrowed 76% from 3Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 4 years, compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings.
New Risk • Mar 13New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.1% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€40m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding).
Major Estimate Revision • Dec 22Consensus revenue estimates increase by 11%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €16.0m to €17.8m. EPS estimate unchanged from -€0.24 at last update. Biotechs industry in the US expected to see average net income growth of 7.6% next year. Consensus price target of US$3.88 unchanged from last update. Share price was steady at US$2.01 over the past week.
New Risk • Dec 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 7.6% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€36m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding).
分析記事 • Nov 28Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Nov 09Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2023 results: €0.07 loss per share (improved from €0.34 loss in 3Q 2022). Net loss: €5.71m (loss narrowed 77% from 3Q 2022). Revenue missed analyst estimates by 60%. Earnings per share (EPS) exceeded analyst estimates by 14%. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
New Risk • Nov 08New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 1.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 1.8% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€35m net loss in 3 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (€4.5m revenue, or US$4.8m). Market cap is less than US$100m (US$98.7m market cap).
New Risk • Oct 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€32m net loss in 3 years). Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (€4.5m revenue, or US$4.8m). Market cap is less than US$100m (US$98.7m market cap).
Major Estimate Revision • Sep 28Consensus revenue estimates increase by 15%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast increased from €18.7m to €21.5m. EPS estimate unchanged from -€0.27 at last update. Biotechs industry in the US expected to see average net income decline 4.0% next year. Consensus price target of US$3.76 unchanged from last update. Share price fell 10% to US$1.33 over the past week.
Major Estimate Revision • Aug 10Consensus revenue estimates fall by 16%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from €23.8m to €19.9m. Forecast losses increased from -€0.238 to -€0.262 per share. Biotechs industry in the US expected to see average net income decline 20% next year. Consensus price target of US$3.80 unchanged from last update. Share price was steady at US$1.49 over the past week.
New Risk • Aug 07New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 4.9% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 4.9% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€37m net loss in 3 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Revenue is less than US$5m (€4.5m revenue, or US$4.9m).
Reported Earnings • Aug 04Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: €0.099 loss per share (improved from €0.21 loss in 2Q 2022). Net loss: €7.99m (loss narrowed 46% from 2Q 2022). Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) also surpassed analyst estimates by 11%. Revenue is expected to decline by 10% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 16%. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • Aug 03Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €135 million.Laboratoires Théa S.A.S. agreed to acquire Sepofarsen and Ultevursen Ophthalmic Assets from ProQR Therapeutics N.V. (NasdaqCM:PRQR) for approximately €135 million on July 31, 2023. Based on the terms and agreements ProQR will receive an initial payment of €12.5 million and will also be eligible to receive up to €135 million in further development, regulatory, and commercial payments as well as additional earn outs of up to high. teens percentage based on commercial sales in the United States and the European Union. The transaction is subject to the satisfaction of certain closing conditions and covenants. The transaction is expected to close in the third quarter of 2023. Lazard B.V. acted as financial advisor and Allen & Overy Amsterdam acted as legal advisor to ProQR Therapeutics. Dentons Europe, Association d'Avocats à Responsabilité Professionnelle Individuelle acted as legal advisor to Laboratoires Théa.
分析記事 • Jul 30Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Major Estimate Revision • May 27Consensus revenue estimates decrease by 25%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €26.7m to €20.0m. EPS estimate unchanged at -€0.243 per share. Biotechs industry in the US expected to see average net income decline 82% next year. Consensus price target of US$3.80 unchanged from last update. Share price fell 8.8% to US$1.72 over the past week.
Major Estimate Revision • May 26Consensus EPS estimates upgraded to €0.24 loss, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €27.2m to €24.5m. 2023 losses expected to reduce from -€0.508 to -€0.243 per share. Biotechs industry in the US expected to see average net income decline 82% next year. Consensus price target of US$3.82 unchanged from last update. Share price fell 4.0% to US$1.67 over the past week.
Price Target Changed • May 25Price target decreased by 9.2% to US$3.82Down from US$4.21, the current price target is an average from 7 analysts. New target price is 117% above last closing price of US$1.76. Stock is up 181% over the past year. The company is forecast to post a net loss per share of €0.19 next year compared to a net loss per share of €0.91 last year.
お知らせ • May 18ProQR Therapeutics N.V. Approves the Appointment of Theresa Heggie and Begoña Carreño as Supervisory Board MemberOn May 17, 2023, ProQR Therapeutics N.V. held its 2023 annual general meeting of shareholders. ProQR shareholders approved the appointment of Theresa Heggie and Begoña Carreño as Supervisory Board member.
Reported Earnings • May 18First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2023 results: €0.11 loss per share (improved from €0.20 loss in 1Q 2022). Net loss: €8.93m (loss narrowed 38% from 1Q 2022). Revenue missed analyst estimates by 47%. Earnings per share (EPS) exceeded analyst estimates by 7.5%. Revenue is expected to decline by 34% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Breakeven Date Change • May 17Forecast to breakeven in 2023The 4 analysts covering ProQR Therapeutics expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €6.73m in 2023.
Reported Earnings • Mar 31Full year 2022 earnings: EPS in line with expectations, revenues disappointFull year 2022 results: €0.91 loss per share. Net loss: €65.1m (loss widened 5.7% from FY 2021). Revenue missed analyst estimates by 66%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to stay flat during the next 3 years compared to a 13% growth forecast for the Biotechs industry in the US.
分析記事 • Mar 17Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Price Target Changed • Dec 23Price target increased to US$3.25Up from US$1.72, the current price target is an average from 6 analysts. New target price is 20% above last closing price of US$2.71. Stock is down 67% over the past year. The company is forecast to post a net loss per share of €0.92 next year compared to a net loss per share of €0.96 last year.
Major Estimate Revision • Nov 16Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €3.98m to €4.20m. Forecast EPS reduced from -€0.80 to -€0.94 per share. Biotechs industry in the US expected to see average net income decline 93% next year. Consensus price target of US$1.72 unchanged from last update. Share price rose 3.4% to US$0.96 over the past week.
Reported Earnings • Nov 11Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: €0.34 loss per share (further deteriorated from €0.22 loss in 3Q 2021). Net loss: €24.4m (loss widened 62% from 3Q 2021). Revenue exceeded analyst estimates by 20%. Earnings per share (EPS) missed analyst estimates by 63%. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings.
Major Estimate Revision • Aug 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €4.73m to €4.25m. EPS estimate increased from -€0.86 to -€0.78 per share. Biotechs industry in the US expected to see average net income decline 77% next year. Consensus price target down from US$2.53 to US$1.80. Share price rose 7.6% to US$0.89 over the past week.
Major Estimate Revision • Aug 11Consensus revenue estimates increase by 25%The consensus outlook for revenues in 2022 has improved. 2022 revenue forecast increased from €3.63m to €4.55m. Forecast losses expected to reduce from -€0.86 to -€0.81 per share. Biotechs industry in the US expected to see average net income decline 46% next year. Consensus price target of US$2.42 unchanged from last update. Share price fell 3.6% to US$0.81 over the past week.
Seeking Alpha • Aug 11ProQR says EU regulator seeks additional trial for lead candidateDutch biotech ProQR Therapeutics N.V. (NASDAQ:PRQR) announced on Thursday that the European Medicines Agency (EMA) recommended an additional pivotal clinical trial before submitting a marketing application for the company’s lead candidate sepofarsen. An investigational RNA therapy, sepofarsen, is designed to target Leber congenital amaurosis 10, a common cause of blindness due to genetic factors in children. Following the EMA feedback, ProQR (PRQR) has decided to look for a strategic partner to further advance its ophthalmology portfolio, which also includes RNA candidate ultevursen (QR-421a) targeted at Usher syndrome and retinitis pigmentosa. Until a partnership is formed and to preserve capital, the company will terminate the ongoing trials for sepofarsen and ultevursen, including Illuminate, Insight, and Brighten studies for sepofarsen, along with Sirius and Helia trials for ultevursen. In addition, ProQR (PRQR) announced a workforce reduction which it said will help extend the cash runway into 2026, along with the decision to wind down trials for sepofarsen and ultevursen. Early this year, the company announced that its pivotal Phase 2/3 study for sepofarsen did not meet the main goal in LCA10.
Reported Earnings • Aug 05Second quarter 2022 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2022 results: €0.21 loss per share (up from €0.24 loss in 2Q 2021). Net loss: €14.9m (loss narrowed 5.5% from 2Q 2021). Revenue exceeded analyst estimates by 21%. Earnings per share (EPS) also surpassed analyst estimates by 8.0%. Over the next year, revenue is expected to shrink by 5.7% compared to a 46% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings.
Major Estimate Revision • May 12Consensus estimates of losses per share improve by 11%The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €3.20m to €3.49m. EPS estimate increased from -€0.92 per share to -€0.82 per share. Biotechs industry in the US expected to see average net income decline 44% next year. Consensus price target down from US$3.17 to US$2.42. Share price fell 20% to US$0.56 over the past week.
Reported Earnings • May 06First quarter 2022 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2022 results: €0.20 loss per share. Net loss: €14.4m (loss widened 15% from 1Q 2021). Revenue exceeded analyst estimates by 59%. Earnings per share (EPS) also surpassed analyst estimates by 16%. Over the next year, revenue is expected to shrink by 4.8% compared to a 41% growth forecast for the industry in the US.
Price Target Changed • Apr 27Price target decreased to US$3.29Down from US$4.86, the current price target is an average from 6 analysts. New target price is 344% above last closing price of US$0.74. Stock is down 88% over the past year. The company is forecast to post a net loss per share of €0.85 next year compared to a net loss per share of €0.96 last year.
Price Target Changed • Apr 14Price target decreased to US$3.64Down from US$4.96, the current price target is an average from 6 analysts. New target price is 363% above last closing price of US$0.79. Stock is down 87% over the past year. The company is forecast to post a net loss per share of €0.88 next year compared to a net loss per share of €0.96 last year.
Reported Earnings • Feb 26Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.96 loss per share (down from €0.93 loss in FY 2020). Net loss: €61.6m (loss widened 32% from FY 2020). Revenue missed analyst estimates by 52%. Earnings per share (EPS) exceeded analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 42%, compared to a 185% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
Price Target Changed • Feb 13Price target decreased to US$13.50Down from US$24.13, the current price target is an average from 7 analysts. New target price is 871% above last closing price of US$1.39. Stock is down 73% over the past year. The company is forecast to post a net loss per share of €0.97 next year compared to a net loss per share of €0.93 last year.
分析記事 • Nov 10Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing MoneyLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Oct 01Investment Case On ProQR Therapeutics Gets More EnticingToday, we revisit ProQR Therapeutics, an intriguing developmental concern for the first time since early this year. The company recently inked a significant collaboration deal with drug giant Eli Lilly which makes its investment case more enticing. We update the investment thesis on ProQR Therapeutics to account for recent events in the paragraphs below.
Major Estimate Revision • Aug 06Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €561.2k to €449.9k. EPS estimate unchanged from -€0.82 per share at last update. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target of US$26.00 unchanged from last update. Share price rose 20% to US$6.26 over the past week.
分析記事 • Aug 04ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • May 13It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This YearCEO Daniel de Boer has done a decent job of delivering relatively good performance at ProQR Therapeutics N.V...
Major Estimate Revision • May 13Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €1.66m to €1.19m. EPS estimate increased from -€1.02 to -€0.93 per share. Biotechs industry in the US expected to see average net income decline 15% next year. Consensus price target down from US$28.33 to US$26.57. Share price rose 2.1% to US$6.32 over the past week.
Price Target Changed • Mar 25Price target increased to US$24.17Up from US$21.50, the current price target is an average from 4 analysts. New target price is 325% above last closing price of US$5.68. Stock is down 4.5% over the past year.